Quick answer
No peer-reviewed paper reports a validated shelf life or solution half-life for a research-grade lyophilized hexarelin vial, so no number should be quoted as fact. What is published falls into other categories: metabolism studies in rats and human serum that identify cleavage by exopeptidases, amidases and endopeptidases (Thomas and colleagues, 2012), and pharmacodynamic studies showing the GH response to repeat exposure fading over hours to weeks. For the vial, rely on the stated storage line (2–8 °C, −20 °C long-term, protect from heat, moisture and light), general peptide-stability principles, and an HPLC check when concentration matters. For laboratory research use only; not for human consumption.
"Half-life" is one of the most searched and least precisely used words in peptide research. For hexarelin it can mean at least three different things, and each has a different answer, or no answer. This article separates them, reports what the published literature supports for each, and then gives a practical plan for a laboratory that needs to know whether its own stock is still what the label says. The material discussed is the research reagent on the hexarelin product page; the broader compound profile is in the hexarelin research overview.
Three meanings of half-life
| Meaning | Question it answers | What is published for hexarelin |
|---|---|---|
| Metabolic (biological) half-life | How fast is the peptide cleared or cleaved in an animal or in serum? | Metabolite identification in rats and in human serum; no value reproduced here because the abstract reports metabolites, not a clearance rate |
| Pharmacodynamic duration | How long does a measured response last after exposure? | GH response timing and desensitization in rats and dogs |
| Shelf life or solution stability | How long does the vial or stock keep its concentration and purity? | No validated figure for the research material; general peptide-stability principles only |
A reader who sees a single number labelled "half-life" in a chart or online post should ask which of the three it belongs to, and for which species, matrix and temperature. A clearance time in a rat has no bearing on how long a reconstituted vial stays intact in a refrigerator.
What the metabolism work shows
The most direct published information on hexarelin's fate in biological matrices comes from sports-drug-testing laboratories, which needed to find urinary markers for the whole GHRP family. Thomas and colleagues administered hexarelin and seven related peptides to rats (orally and intravenously) and incubated them with human serum and recombinant amidase, then analyzed urine by high-resolution mass spectrometry. They identified 28 metabolites across the peptides, at least three for each, and reported that all were formed by exopeptidase (amino- or carboxy-terminal), amidase or endopeptidase activity (Thomas and colleagues, 2012).
Two takeaways are relevant to a research laboratory. First, the C-terminal amide of hexarelin is a site of enzymatic attack in biological matrices, so serum-containing media or tissue homogenates are not neutral diluents. Second, the same study confirmed key metabolites in a human serum model, which means protease activity in a cell-culture medium with serum can change the effective concentration of hexarelin during an experiment. That is a design point for in vitro work: measure or control for it rather than assuming nominal concentration is delivered throughout.
A related structure-activity paper tested GHRPs including hexarelin in a receptor-binding assay against labelled ghrelin and reported that chemical modifications at positions 1, 2, 3 and 7 of the common scaffold influence receptor activity, which matters when a degradation product might keep partial receptor activity (Ferro and colleagues, 2017). A fragment that still binds GHS-R1a can make a degraded stock look active.
Pharmacodynamic duration is not stability
Animal papers describe how quickly the GH response appears and how it changes with repeated exposure. In rats, plasma GH peaked within 40 minutes of the start of a continuous infusion and then returned to basal levels while the infusion continued (Conley and colleagues, 1998). In dogs, the response to a challenge rose to a maximum at week 3 and fell by week 6 (Rigamonti and colleagues, 1999). These findings describe receptor and pituitary behavior. A fading response says nothing about whether the peptide in the pump or the vial was degrading; the infusion in the rat study continued while the response waned. Confusing the two is the commonest way a pharmacodynamic observation turns into an unfounded stability claim.
What the sequence implies about chemical stability
Hexarelin is His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2, a six-residue peptide with a C-terminal amide and two D-amino acids. Reading the sequence against known degradation pathways gives informed expectations. These are inferences from structure and general peptide science, not hexarelin-specific measurements.
| Feature | General stability consequence | Practical handling response |
|---|---|---|
| Two tryptophan-type residues | Aromatic side chains can undergo oxidation and photo-degradation under forced conditions (Hawe and colleagues, 2012) | Keep vials boxed; avoid bench light; avoid oxidizing contaminants |
| D-amino-acid residues | Resist many proteases, so enzymatic breakdown is slower in biological matrices than for all-L peptides | Does not protect against chemical oxidation or adsorption |
| No asparagine, glutamine or aspartate | Deamidation and isomerization at those residues, a main solution pathway for many peptides (Manning and colleagues, 2010), has no obvious site here | Do not assume the absence of other pathways |
| Histidine and lysine | Basic residues; charged at neutral pH, which affects adsorption to negatively charged glass | Low-binding tubes; avoid very dilute stocks held for long periods |
| C-terminal amide | Target for amidases in serum-containing matrices | Account for serum protease activity in cell-culture designs |
The general principle that the dry state is far more stable than solution (Manning and colleagues, 2010; Wang, 1999) applies to every lyophilized peptide, hexarelin included. Reconstitution starts the clock on solution-phase processes, and each freeze–thaw cycle adds ice-interface stress.
Storage tiers that follow from the product page
The product page states one storage line: refrigerate at 2–8 °C, −20 °C for long-term, and protect from heat, moisture and light. The table expands that into the states a vial passes through, without inventing day-counts that no paper supports.
| State | Temperature tier | Handling note |
|---|---|---|
| Sealed lyophilized vial, near-term use | 2–8 °C | Keep boxed; let the vial reach room temperature before opening so condensation does not form |
| Sealed lyophilized vial, reserve | −20 °C | Avoid frost-free units with warm defrost cycles |
| Reconstituted stock for repeated entry | 2–8 °C | Swab the stopper each time; record date and concentration; inspect before use |
| Single-use aliquots | −20 °C | Thaw once; do not refreeze; label with lot and freeze date |
| Dilute working solutions | Prepared on the day | Surface loss is proportionally largest at low concentration (Goebel-Stengel and colleagues, 2011) |
More on tiering is in storing research peptides, and the logic of how long solutions hold is in how long do reconstituted peptides last.
How a laboratory can verify its own stock
Where an experiment depends on exact concentration over days or weeks, the sound approach is to measure instead of assume. A minimal stability check uses a reversed-phase HPLC method (see understanding HPLC purity) and follows these steps:
- Reconstitute one vial, divide into identical low-binding aliquots, and keep one at each storage condition under test.
- Run the main peak area and impurity profile at time zero from a fresh aliquot.
- Re-run at predetermined times, always from an untouched aliquot, using the same method and a freshly prepared reference.
- Record peak area relative to time zero, new peaks and any visual change. Mass spectrometry on new peaks distinguishes oxidation (a +16 Da shift) from other changes.
- Decide the acceptance limit before the study, for example the percentage of main peak that must remain, and state it in the notebook.
Visual inspection detects gross failure only. A clear, colorless solution is necessary but not sufficient, as discussed in peptide vial appearance. Where a certificate has been published for a lot, it is listed on the COA page, and the testing approach is described in hexarelin purity testing.
Matrix effects: why the same stock behaves differently in different media
A stock that is stable in water for a week can lose potency within hours in a different matrix, so stability has to be stated per medium. Four common matrices differ in ways that matter for a hexapeptide:
- Water or dilute acid. No enzymes, low ionic strength. The least demanding environment, and the one where adsorption to surfaces is usually the main source of apparent loss.
- Physiological buffer. Neutral pH and salts change charge states and can slightly increase oxidation rates compared with a slightly acidic stock.
- Serum-containing culture medium. Exopeptidases and amidases are present, and the metabolism literature shows these enzymes act on the GHRP family (Thomas and colleagues, 2012). Effective concentration falls over hours.
- Tissue homogenate or perfusate with cells. Cell-surface proteases and uptake add further losses; time-course sampling is the only way to know the exposure.
For perfused-organ and culture work, a practical approach is to add the peptide at the last possible moment, sample the medium at the beginning and end of the exposure, and report the measured concentration alongside the nominal one. This is straightforward with a validated LC-MS method and avoids attributing biological effects to a concentration that was never delivered. Serial dilutions should be made in low-binding labware and used immediately, because the lowest concentrations are the ones most affected by surface loss.
Recording stability evidence for your own lots
Because no external stability number exists, the laboratory's own record is the evidence. Keep, for each lot: the certificate reference, receipt date and appearance of the cake, reconstitution date, diluent, concentration, the storage location, each date the vial was entered, freeze–thaw count of every aliquot used, and any HPLC re-check with its date and result. When an assay result drifts, this record is the first place to look, and it is the only way to separate a biological change from a change in the reagent.
Claims to handle with caution
Several claims about hexarelin circulate without a primary source. A specific half-life in minutes quoted for the vial or for reconstituted solution, a precise number of days of refrigerated stability, and a statement that hexarelin is "stable at room temperature for weeks" are examples. None is supported by a paper in the sources cited here. If such a figure appears, look for the method, the matrix, the temperature and the measurement; if those are absent, the figure is an assertion.
Related reading
- Hexarelin research overview
- What is hexarelin?
- Storing research peptides
- How long do reconstituted peptides last?
- Hexarelin purity testing
- Research peptide catalog
Frequently asked questions
What is the half-life of hexarelin?
It depends on which half-life is meant. Metabolism studies identify enzymatic cleavage products in rats and human serum, pharmacodynamic studies describe how the GH response changes over time, and no validated shelf life exists for the research vial. No single number is supported by the sources cited.
Is there a published shelf life for reconstituted hexarelin?
No validated figure for the research-grade vial has been found in the peer-reviewed literature. Laboratories rely on the storage line, general peptide principles and an HPLC check when concentration is critical.
How should hexarelin be stored?
The product page states 2–8 °C, −20 °C for long-term storage, and protection from heat, moisture and light. Freeze single-use aliquots instead of refreezing one vial.
Does the D-amino-acid content make hexarelin stable?
It slows protease cleavage in biological matrices, but it does not prevent oxidation of tryptophan-type residues, light damage or adsorption to surfaces.
Can serum in cell culture medium change hexarelin concentration?
Metabolism work found amidase and peptidase cleavage in human serum models, so concentration may fall during an experiment in serum-containing medium. Measure it or control for it.
Does a fading GH response mean the peptide has degraded?
No. In rat and dog studies the response fell while exposure continued, which reflects receptor and pituitary adaptation, not chemical degradation.
How can I check whether my hexarelin stock is still intact?
Run reversed-phase HPLC on aliquots kept under each storage condition at fixed time points against a fresh reference, and examine new peaks by mass spectrometry.
Related reading: Hexarelin Reconstitution Calculator: Math and Planning, Hexarelin Preclinical Studies: A Review by Model, Hexarelin Lab Applications: Assays and Model Systems.
References
- Thomas A, Delahaut P, Krug O, Schänzer W, Thevis M. Metabolism of growth hormone releasing peptides. Anal Chem. 2012;84(23):10252-9. doi:10.1021/ac302034w
- Ferro P, Krotov G, Zvereva I, Rodchenkov G, Segura J. Structure-activity relationship for peptídic growth hormone secretagogues. Drug Test Anal. 2017;9(1):87-95. doi:10.1002/dta.1947
- Conley LK, Gaillard RC, Giustina A, Brogan RS, Wehrenberg WB. Effects of repeated doses and continuous infusions of the growth hormone-releasing peptide hexarelin in conscious male rats. J Endocrinol. 1998;158(3):367-75. doi:10.1677/joe.0.1580367
- Rigamonti AE, Cella SG, Marazzi N, Müller EE. Six-week treatment with hexarelin in young dogs: evaluation of the GH responsiveness to acute hexarelin or GHRH administration, and of the orexigenic effect of hexarelin. Eur J Endocrinol. 1999;141(3):313-20. doi:10.1530/eje.0.1410313
- Hawe A, Wiggenhorn M, van de Weert M, Garbe JHO, Mahler HC, Jiskoot W. Forced degradation of therapeutic proteins. J Pharm Sci. 2012;101(3):895-913. doi:10.1002/jps.22812
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. doi:10.1007/s11095-009-0045-6
- Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm. 1999;185(2):129-188. doi:10.1016/S0378-5173(99)00152-0
- Goebel-Stengel M, Stengel A, Taché Y, Reeve JR Jr. The importance of using the optimal plasticware and glassware in studies involving peptides. Anal Biochem. 2011;414(1):38-46. doi:10.1016/j.ab.2011.02.009
